GI 6207

Drug Profile

GI 6207

Alternative Names: GI-6207; Recombinant Saccharomyces cerevisiae-CEA (610D)

Latest Information Update: 29 Jun 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlobeImmune
  • Developer GlobeImmune; NantKwest
  • Class Cancer vaccines; Yeasts
  • Mechanism of Action Carcinoembryonic antigen inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Thyroid cancer
  • Phase I/II Breast cancer; Colorectal cancer; Pancreatic cancer
  • No development reported Solid tumours

Most Recent Events

  • 20 Jun 2018 NantKwest plans the QUILT-3.088 phase II trial for Pancreatic Cancer (Metastatic disease) in USA , (NCT03563144)
  • 20 Jun 2018 NantKwest plans a phase II QUILT-3.057 trial for Triple negative breast cancer (First-line therapy, Combination therapy, Neoadjuvant therapy) in USA (NCT03554109)
  • 25 May 2018 Phase-I/II clinical trials in Colorectal cancer (Chemotherapy-induced, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top